Benefits of Kava

Evidence-Based Benefits

• Anxiety reduction (Cochrane level evidence) — Pittler & Ernst (2003) systematically reviewed 11 RCTs in the Cochrane Database and concluded kava extract significantly reduced anxiety compared to placebo, with a weighted mean difference of 3.9 points on the Hamilton Anxiety Scale
• Generalized anxiety disorder — Sarris et al. (2013) conducted a rigorous 6-week RCT of 75 patients with GAD, finding 120-240mg kavalactones daily (titrated based on response) significantly reduced anxiety compared to placebo, with a remission rate of 26% vs 6% for placebo
• Multi-target anxiolytic mechanism — kavalactones modulate GABA-A receptors (kavain), block voltage-gated sodium channels (reducing neuronal excitability), inhibit norepinephrine reuptake, and modulate MAO-B activity, providing broad-spectrum anxiety relief through complementary pathways
• Cognitive preservation — unlike benzodiazepines, kava does not impair cognitive function at therapeutic doses. Sarris et al. found no cognitive side effects, and some studies suggest mild cognitive enhancement alongside anxiety reduction
• Muscle relaxation — kavalactones have direct skeletal muscle relaxant properties, providing physical relaxation that complements the psychological anxiolytic effects, beneficial for tension-type anxiety and stress-related muscle tension

What the Research Says

Kava is a well-researched herbal anxiolytic supported by a robust evidence base. A systematic review and meta-analysis by Pittler and Ernst (2003) evaluated 11 randomized controlled trials (RCTs) involving 645 participants, demonstrating that kava significantly outperformed placebo in reducing anxiety symptoms, as measured by the Hamilton Anxiety Scale (WMD 3.9). Further support comes from a double-blind, randomized, placebo-controlled study by Sarris et al. (2013), which found significant reductions in generalized anxiety disorder (GAD) symptoms after six weeks of treatment with kavalactones.

Regarding safety, concerns about hepatotoxicity have been raised, primarily linked to non-noble cultivars, the use of stem and leaf material, and extraction methods involving ethanol or acetone. However, Teschke et al. (2012) conducted a comprehensive review of liver safety data and concluded that aqueous root extracts from noble cultivars exhibit an excellent safety profile, aligning with centuries of traditional Pacific Island use without reports of liver toxicity.

Additional studies provide further insights: Ooi et al. (2018) reviewed 12 studies involving 130 participants, noting limited but promising evidence for kava's efficacy in treating GAD. Pittler and Ernst (2000) analyzed seven trials, confirming kava extract's significant superiority over placebo for anxiety treatment. Witte et al. (2005) meta-analyzed six RCTs with 643 patients, finding that the WS1490 kava extract significantly reduced anxiety symptoms compared to placebo, with an odds ratio of 3.3 (CI: 2.09-5.22). Economidis et al. (2025) highlighted kava's cultural and economic significance in Pacific Islander communities while noting the need for clearer evidence on its health effects.

Overall, kava demonstrates strong efficacy for anxiety management when derived from noble cultivars and prepared appropriately, with a favorable safety profile under these conditions.

Related Conditions